Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.72 |
| ▸ | CDK2 | P24941 | 13/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146697 | 0.90 | GSK3B (0.71) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL27369472 | 0.89 | GSK3B (0.76) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953189 | 0.87 | GSK3B (0.71) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL27370456 | 0.86 | GSK3B (0.69) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL30356813 | 0.85 | GSK3B (0.70) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953359 | 0.84 | GSK3B (0.69) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12953029 | 0.84 | GSK3B (1.00) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953181 | 0.80 | GSK3B (0.64) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL12954514 | 0.79 | GSK3B (0.61) | GSK3BCDK2CCNE1MEN1NPC1 | |
| SCHEMBL27370860 | 0.78 | CDK2 (0.47) | GSK3BCDK2CCNE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054953-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023059582-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |